Other languages Cutia Therapeutics

Equities

2487

KYG2606C1006

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-05-31 am EDT			5-day change	1st Jan Change
7.2 ^HKD	+2.86%		-9.43%	-34.43%

May. 31	Cutia Therapeutics Presents Acne Drug's Phase III Clinical Trial Results at Asian Dermatology Congress	MT
May. 30	Cutia Therapeutics Obtains Clinical Trial Approval in China for Dermatitis Drug	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cutia Therapeutics Presents Acne Drug's Phase III Clinical Trial Results at Asian Dermatology Congress	May. 30
Cutia Therapeutics Obtains Clinical Trial Approval in China for Dermatitis Drug	May. 30
Cutia Therapeutics Announces Investigational New Drug Application of CU-10101 for Atopic Dermatitis Approved by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China	May. 30
Cutia Therapeutics' Unit Receives Jiangsu Drug Manufacturing Certificate	Apr. 29
Cutia Therapeutics Submits NDA for Androgenetic Alopecia Treatment Spray; Shares Jump 6%	Apr. 29
Cutia Therapeutics Submits New Drug Application for Cu-40102 (Topical Finasteride Spray) in Hong Kong, PRC	Apr. 29
Cutia Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
Cutia Therapeutics' Atopic Dermatitis Drug's IND Application Accepted by China's NMPA	Mar. 26
Cutia Therapeutics Announces the Investigational New Drug Application of CU-10101 (Topical Novel Small Molecule Agent) for the Treatment of Mild to Moderate Atopic Dermatitis Accepted by the Center for Drug Evaluation of the National Medical Products Administration	Mar. 26
Cutia Therapeutics Included in Two FTSE Indices	Mar. 18
Cutia Therapeutics Announces Completion of Phase I Clinical Trial of CU-20401	Feb. 27
Cutia Therapeutics Included in Hang Seng Family of Indexes	Feb. 19
Cutia's Phase 3 Clinical Trial for Analgesic Cream Reaches Primary Endpoint; Shares Surge 12%	Jan. 30
China Accepts Cutia Therapeutics's New Drug Application for Alopecia Treatment; Shares Surge 13%	Jan. 30
Cutia Therapeutics Announces New Drug Application for CU-40102 (Topical Finasteride Spray) Accepted by the National Medical Products Administration	Jan. 30
Cutia Therapeutics Doses First Patient for Anti-Obesity Injectable	Jan. 03
Cutia Therapeutics Announces First Patient Enrollment in the Phase II Clinical Trial of CU-20401	Jan. 02
Cutia Therapeutics Publishes Results of Phase 3 Trial for Alopecia, Acne Treatments in China	Dec. 10
Cutia Therapeutics Announces Results of Phase III Clinical Trials of CU-40102 (Topical Finasteride Spray) and CU-10201 (Topical 4% Minocycline Foam) in the People's Republic of China	Dec. 10
Certain Ordinary Shares of Cutia Therapeutics are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	Dec. 10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cutia Therapeutics

Equities

2487

KYG2606C1006

Other languages

Filters